(Total Views: 389)
Posted On: 04/27/2021 7:23:11 AM
Post# of 653
$RLFTF DD by OU2 on Yh-0: Remember - As part of a new agreement with AdVita Lifescience, Relief Therapeutics will acquire the intellectual rights for the specifications and potential applications of an inhaled formulation of RLF-100 (aviptadil).
By acquiring the rights to AdVita’s therapy formulation, Relief also will accelerate and secure RLF-100’s future development as an inhaled therapy for lung diseases, such as pulmonary sarcoidosis, that are associated with COVID-19. Other lung diseases associated with COVID-19, which also could potentially be treated by RLF-100, include checkpoint inhibitor-induced pneumonitis, and acute respiratory distress syndrome (ARDS).
Of note, the other current formulation of RLF-100 is as an intravenous (into-the-vein) infusion.
Relief is getting the intellectual rights to RLF-100 as part of a binding term agreement in which it will acquire all shares of AdVita, along with several company assets.
“AdVita’s intellectual property around inhaled formulations of Aviptadil and its team’s expertise with Aviptadil will be invaluable as we move forward with the development of the inhaled formulation of RLF-100 for the treatment of COVID-19-related ARDS, as well as other potential lung disease indications, such as pulmonary Sarcoidosis,” Jack Weinstein, chief financial officer and treasurer of Relief, said in a press release.
“We look forward to initiating the development of inhaled RLF-100 in Europe within the coming months for COVID-19 patients using inhaled Aviptadil.
By acquiring the rights to AdVita’s therapy formulation, Relief also will accelerate and secure RLF-100’s future development as an inhaled therapy for lung diseases, such as pulmonary sarcoidosis, that are associated with COVID-19. Other lung diseases associated with COVID-19, which also could potentially be treated by RLF-100, include checkpoint inhibitor-induced pneumonitis, and acute respiratory distress syndrome (ARDS).
Of note, the other current formulation of RLF-100 is as an intravenous (into-the-vein) infusion.
Relief is getting the intellectual rights to RLF-100 as part of a binding term agreement in which it will acquire all shares of AdVita, along with several company assets.
“AdVita’s intellectual property around inhaled formulations of Aviptadil and its team’s expertise with Aviptadil will be invaluable as we move forward with the development of the inhaled formulation of RLF-100 for the treatment of COVID-19-related ARDS, as well as other potential lung disease indications, such as pulmonary Sarcoidosis,” Jack Weinstein, chief financial officer and treasurer of Relief, said in a press release.
“We look forward to initiating the development of inhaled RLF-100 in Europe within the coming months for COVID-19 patients using inhaled Aviptadil.
(0)
(0)
$MJ
